Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Safety and efficacy of peptide...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience

Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience

Show other versions (1)
Bibliographic Details
Main Authors: Vineeth Sukrithan, Heather Armbruster, Sherise Rogers, Sherry Mori Vogt, Cassandra Grenade, Claire Verschraegen, Ye Zhou, Ashima Goyal, Mona Natwa, Akram Hussein, Hallie Barr, Dramane Konate, Rochelle Batdorf, Andrew Brown, Bonnie Williams, Songzhu Zhao, Lai Wei, Menglin Xu, Manisha H. Shah, Bhavana Konda
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11095666/?tool=EBI
  • Holdings
  • Description
  • Other Versions (1)
  • Similar Items
  • Staff View

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11095666/?tool=EBI

Similar Items

  • Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
    by: Vineeth Sukrithan, et al.
    Published: (2024-01-01)
  • Kinase inhibitors in thyroid cancers
    by: Vineeth Sukrithan, et al.
    Published: (2024-02-01)
  • Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib
    by: Vineeth Sukrithan, et al.
    Published: (2023-01-01)
  • Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer
    by: Fadi Nabhan, et al.
    Published: (2021-01-01)
  • Enhanced phytoremediation strategy for sustainable management of heavy metals and radionuclides
    by: B.S. Manisha Singh, et al.
    Published: (2022-05-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs